JOSÉ LUIS
GONZÁLEZ LARRIBA
Catedrático de universidad
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (21)
2024
-
Difficulties on the access to innovative targeted therapies for lung cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
2022
-
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79
-
SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2020
-
Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
BMC Psychology, Vol. 8, Núm. 1
-
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Lung Cancer, Vol. 147, pp. 83-90
2018
-
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38
2017
-
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: The necessity of repeated molecular analysis
Translational Lung Cancer Research, Vol. 6, pp. S21-S34
-
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226
-
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action
Targeted Oncology, Vol. 12, Núm. 1, pp. 19-35
-
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226
2011
-
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653
-
Sorafenib in renal cell carcinoma
Critical Reviews in Oncology/Hematology, Vol. 80, Núm. 2, pp. 314-322
2010
-
Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
European Journal of Cancer Care, Vol. 19, Núm. 5, pp. 648-655
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
-
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
2009
-
Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer
Cancer Chemotherapy and Pharmacology
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2000
-
Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
European Journal of Cancer, Vol. 36, Núm. 18, pp. 2344-2352